Literature DB >> 12577196

Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy.

Don E Smith1, Jeff Hudson, Allison Martin, Judith Freund, Matthew R Griffiths, Sue Kalnins, Matthew Law, Andrew Carr, David A Cooper.   

Abstract

BACKGROUND: The accurate measurement of total body and subcutaneous fat is essential if therapeutic interventions, aimed at preventing or reversing lipodystrophy syndrome, are to be adequately assessed. The aim of this study was to investigate the variability of dual-energy X-ray absorptiometry (DEXA) scans analysis performed at local sites compared to central analysis in a multicenter clinical trial.
METHOD: The PIILR study was a multicenter randomized clinical trial in which 80 HIV-infected patients with physician-documented lipodystrophy had serial measurements of body composition performed with Lunar DEXA scans. Scans were analyzed at local sites and then were reanalyzed centrally.
RESULTS: DEXA scans from 73 patients who completed 24 weeks study were compared. Greater variation in the locally analyzed results than in the centrally reanalyzed data was noted, with arm, leg, and combined limb fat being most divergent between the local and centralized assessments (ratio of local to central standard deviation was 1.28, 1.31, and 1.35, respectively). The magnitude of this variance was enough to alter statistically relevant differences between study populations.
CONCLUSION: Quality assurance is an important issue in the use of DEXA scans to determine body fat composition in multicenter research studies. A central quality assurance site should be incorporated to reduce variability in results.

Entities:  

Mesh:

Year:  2003        PMID: 12577196     DOI: 10.1310/WRL8-DWH1-7VQL-AK81

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN: 1528-4336


  3 in total

1.  Official position of the Brazilian Association of Bone Assessment and Metabolism (ABRASSO) on the evaluation of body composition by densitometry: part I (technical aspects)-general concepts, indications, acquisition, and analysis.

Authors:  Sergio Setsuo Maeda; Barbara Santarosa Emo Peters; Lígia Araújo Martini; Hannah Karen Moreira Antunes; Maria Cristina Gonzalez; Henrique Pierotti Arantes; Carla M Prado; Camila Lemos Pinto; Iana Mizumukai de Araújo; Francisco José Albuquerque de Paula; Joao Lindolfo Cunha Borges; Ben-Hur Albergaria; Marcela Ushida; Guilherme Cardenaz de Souza; Laura Maria Carvalho de Mendonça; Mirley do Prado; Marcelo de Medeiros Pinheiro
Journal:  Adv Rheumatol       Date:  2022-03-20

2.  A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122).

Authors:  Lawrence Berk; Jennifer James; Anna Schwartz; Eugen Hug; Anand Mahadevan; Michael Samuels; Lisa Kachnic
Journal:  Support Care Cancer       Date:  2008-02-22       Impact factor: 3.603

3.  Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

Authors:  Richard H Haubrich; Sharon A Riddler; A Gregory DiRienzo; Lauren Komarow; William G Powderly; Karin Klingman; Kevin W Garren; David L Butcher; James F Rooney; David W Haas; John W Mellors; Diane V Havlir
Journal:  AIDS       Date:  2009-06-01       Impact factor: 4.177

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.